Biomedical subjects

J M Alby

Publications and source records attributed to J M Alby.

At least 19 recordsLinked to original sources

PubMed1990

A double-blind multicentre comparison of remoxipride, at two dose levels, and haloperidol.

A total of 186 patients who met the DSM-III criteria for schizophrenia were admitted to a double-blind randomized multicentre trial in which the efficacy and safety of remoxipride at two dose levels was compared with those of haloperidol. Over a period of six weeks the patients received remoxipride 100-300 mg/day (n = 60), remoxipride 200-600 mg/day (n = 61), or haloperidol 10-30 mg/day (n = 64). There was no significant difference between the three treated groups with regard to the Brief Psychiatric Rating Scale (BPRS) and Clinical Global Impression (CGI) scores obtained. Remoxipride, at both dosage ranges used, thus had comparable therapeutic efficacy to that of haloperidol. In contrast, extrapyramidal symptoms occurred significantly more frequently in the group treated with haloperidol. Laboratory tests and cardiovascular investigations showed no specific drug effect in any of the treated patients. Remoxipride is thus effective in acute treatment of schizophrenia at both dosage levels and has an advantage over haloperidol in neurological acceptability.

Adolescent↗

PubMed1987

[Construction and preliminary validation of an anxiety scale, the FARD (Ferreri anxiety rating diagram)].

The complexity of the anxious disease does not facilitate the clinical approach. That the reason why the authors have developed a rating scale based on a descriptive symptomatology to find out a diagnosis, to rate the severity of illness and to facilitate the pharmaceutical prescription. To develop a skill needed by general practitioners as well as specialists, Prof. M. Ferreri worked with pools of medical doctors to isolate the more frequent items in the anxious symptomatology. So they pointed out a first group of 14 items. A first statistical approach was to compare the new scale with the well-known Hamilton anxiety scale by the way of a sample of 81 ratings. After a first factor analysis, a sub-group of 12 items were definitely retained. These items were split in 4 factors which permitted to present the factorial results in diagram [Acta psychiat. belg., 87, 704-713 (1987)].

Adult↗

PubMed1982

[Anxiety states and bromazepam (author's transl)].

In the study reported here 73 ambulatory patients with neurotic or reactional anxiety state were treated with bromazepam (Lexomil) 6 to 12 mg/24 hours in 3 divided doses with a double dose at night. Treatment lasted from 28 days (8 patients) to 60 days or more (42 patients). Results were excellent or good in 43 cases, with rapid improvement in the psychic component of anxiety. Twelve of the 15 patient s who took bromazepam 4 hours before going to bed plus a hypnotic at night showed improvement in the quality of sleep. During weaning of ambulatory alcoholic subjects by gradual withdrawal of alcoholic beverages, bromazepam proved useful in reducing the anxiety load. The drug was generally well tolerated.

Adult↗

PubMed1981